Supreme Court focuses on ‘pay for delay’ deals
WASHINGTON—”Pay for delay” deals between big pharmaceutical companies and generic drug competitors are going before the United States Supreme Court.
Federal regulators are pressing the high court to stop big pharmaceutical companies from paying generic drug competitors to delay their releases of cheaper versions of brand name drugs.
The Obama Administration says the so-called “pay for delay” deals profit the drug companies while harming consumers by denying them price declines.
Instead, the deals add $3.5 billion each year to Americans’ drug bills.